Home > Insider Trading > Filing (0001209191-17-058948)

Filing Details

Accession Number:: 0001209191-17-058948
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-02 17:54:45
Reporting Period:: 2017-10-31

Accepted Time:: 2017-11-02 17:54:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704317	Vlad Coric	C/O Biohaven Pharmaceuticals, Inc. 234 Church Street New Haven CT 06510	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2017-10-31	25,828	$29.04	624,172	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-10-31	23,122	$29.96	601,050	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-10-31	1,050	$30.51	600,000	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-10-31	25,827	$29.04	624,173	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-10-31	23,123	$29.96	601,050	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-10-31	1,050	$30.51	600,000	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-11-01	18,074	$29.10	581,926	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-11-01	6,926	$29.62	575,000	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-11-01	18,074	$29.10	581,926	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2017-11-01	6,926	$29.62	575,000	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.38 - $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
These shares are held by The Vladimir Coric Family Trust 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $30.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.44 - $30.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The shares are held by The Vladimir Coric Marital Trust 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.45 - $29.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (10) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.45 - $29.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (11) to this Form 4.